Streetbeat News

Earnings

MSFT

The article provides an in-depth competitor analysis of Microsoft (NASDAQ:MSFT) and its position within the Software industry, comparing financial metrics like P/E, P/B, P/S ratios, ROE, EBITDA, gross profit, and revenue growth against its major competitors. Microsoft shows potential for growth with a reasonable P/E ratio, suggests undervaluation with its P/B ratio, but its P/S ratio could indicate overvaluation. Its ROE is below the industry average, yet it has significantly higher EBITDA and gross profit, indicating strong profitability. The company's revenue growth outpaces the industry average, suggesting a positive outlook.

Portfolio Pulse from Benzinga Insights

April 29, 2024 | 3:00 pm

OND

SOCL

SPOT

Daniel Ek, Spotify's co-founder, sold 650,000 shares for about $179 million, still holding a 7% stake. Spotify's stock has risen 267% since late 2022. Ek plans to invest $1 billion in European tech and climate startups. Spotify reported a Q1 2024 revenue of $3.95 billion, a 20% increase year-on-year, with an EPS of $1.05, beating consensus. Analysts are optimistic about Spotify's revenue growth and profitability. Spotify shares are part of the Global X Social Media ETF (SOCL) and ProShares On-Demand ETF (OND).

Portfolio Pulse from Anusuya Lahiri

April 29, 2024 | 3:00 pm

RVTY

Revvity shares surged following the announcement of their Q1 financial results, which exceeded market expectations.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 2:49 pm

DCPH

HTLF

TSLA

Stocks like Tesla, Deciphera Pharmaceuticals, and Heartland Financial saw significant movements. Tesla partnered with Baidu for Full Self-Driving in China, causing a 10.5% jump. Deciphera Pharmaceuticals surged 73% after an acquisition announcement by ONO Pharmaceutical. Heartland Financial rose 17.2% following UMB Financial's acquisition announcement. Other stocks also recorded gains due to various positive developments, including FDA approvals, financial settlements, and analyst upgrades.

Portfolio Pulse from Avi Kapoor

April 29, 2024 | 2:47 pm

AMZN

Amazon.com Inc (NASDAQ:AMZN) is set to report its Q1 earnings with expectations of 78 cents EPS and $133.1 billion in revenues. The stock has seen a 71.10% increase over the past year and an 18.22% YTD rise, buoyed by its strong positioning in AI, cloud computing, and e-commerce. Investors are watching AWS performance, digital advertising market-share gains, and the impact of price increases on third-party sellers. Amazon's focus on profitability, operational efficiency, and strategic investments in robotic automation are key. Technical analysis indicates a bullish trend, with a 17% upside as per Wall Street analysts.

Portfolio Pulse from Surbhi Jain

April 29, 2024 | 2:29 pm

BEN

Franklin Resources reported worse-than-expected Q2 adjusted EPS results, leading to a decline in its share price.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 2:26 pm

TFFP

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) announced positive Phase 2 trial data for Tacrolimus Inhalation Powder (TFF TAC) for lung transplant rejection prevention, presented at the ISHLT Annual Meeting. The data show TFF TAC prevents rejection with lower doses and systemic exposures than oral tacrolimus, and normalizes rejection-related gene expressions. The company plans to advance the program into potentially registrational testing.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 2:01 pm

C

Financial analysts have observed a bullish trend in Citigroup (NYSE:C) options, with 75% of trades being bullish. Significant activity was noted in options with strike prices ranging from $50.0 to $75.0. The analysis of volume and open interest trends for these options provides insights into liquidity and interest levels. Citigroup's current market performance shows a slight increase in stock price to $62.88, with a potential approach to overbought territory according to RSI values. The next earnings report is expected in 74 days.

Portfolio Pulse from Benzinga Insights

April 29, 2024 | 2:01 pm

AXSM

Axsome Therapeutics (NASDAQ:AXSM) has received diverse analyst ratings over the last three months, with a current average 12-month price target of $131.89, reflecting a 6.52% increase from the previous average of $123.82. The company, a clinical-stage biopharmaceutical focused on CNS disorders, has shown a revenue growth of 193.5% as of December 31, 2023, but struggles with profitability and operational efficiency, indicated by a net margin of -137.92% and ROE of -42.85%.

Portfolio Pulse from Benzinga Insights

April 29, 2024 | 2:01 pm

COP

In the last three months, 12 analysts have provided diverse evaluations for ConocoPhillips (NYSE:COP), with recent ratings showing a mix of bullish and somewhat bullish sentiments. The average 12-month price target for COP has risen to $145.58, indicating a positive outlook. Analyst actions include both upgrades and downgrades, reflecting dynamic market conditions and company performance. Despite a robust market position, ConocoPhillips has faced a revenue decline of -20.63% and challenges in profitability and asset management.

Portfolio Pulse from Benzinga Insights

April 29, 2024 | 2:00 pm